YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Stock data | 2024 | Change |
---|---|---|
Price | $2.54 | N/A |
Market Cap | $236.37M | N/A |
Shares Outstanding | 93.06M | N/A |
Employees | 773.00 | N/A |